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of ICC, in a setting of 70% vaccination coverage. The incremental ratio of cost-
effectiveness (IRCE) was R$ 1,200 for each year of quality-adjusted life (QALY) 
saved. The sensitivity analysis confirms the robustness of this result, and 
duration of immunity was the parameter with greater variation in. 
CONCLUSIONS: Vaccination has a favorable profile in terms of cost-utility, and 
its inclusion in the immunization schedule would result in substantial reduction 
in incidence and mortality of ICC in amazonic region of Brazil.  
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OBJECTIVES: The prevalence of Autism Spectrum Disorders (ASDs) has been 
increasing lately and treatment is expensive. Private insurers have historically 
provided lesser coverage for autism-related services than public insurers. This 
study compared the differences in health care expenditures and utilization 
between publicly and privately insured children with ASDs. METHODS: Data 
were from years 1997-2010 of the Medical Expenditure Panel Survey. 477 children 
with ASDs, of which 274 were privately insured and 184 had public insurance 
only, were identified. Expenditure measures (in 2010 dollars) included total 
health, home health and prescription expenditures and out-of-pocket 
expenditures on health and drugs. Utilization measures included the number of 
office-based visits, home health days and prescriptions. Generalized linear 
models, adjusted for sociodemographics and health status, were used to model 
utilization and expenditure to account for their skewness. STATA survey 
commands generated nationally representative estimates. RESULTS: Average 
total health care expenses were comparable for publicly and privately insured 
children with the latter having much higher out-of-pocket expenses ($1137.807 
vs $199.244). Publicly insured children used more prescriptions (13.52 vs 9.19) 
with lower out-of pocket expenses ($103.170 vs $206.964), and used more home 
health services (19.39 vs 7.67) with higher costs ($3,118.28 vs $782.43). After 
adjusting for sociodemographic differences and health status, no statistically 
significant differences in total health expenditures and utilization measures 
remained. However, publicly insured children spent 79% less (p < 0.000) and 63% 
less (p = 0.001) on average than privately insured children on out-of-pocket 
health and prescription expenditures respectively. CONCLUSIONS: Higher out-
of-pocket expenditures on health services and prescriptions for privately-insured 
children may be an indication of lower coverage for autism-related health 
services. State policies should correct this anomaly to reduce the burden on 
public insurers, as well as provide children with ASDs more options to get 
expensive treatment options covered.  
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OBJECTIVES: To determine the dose relativity of sevelamer hydrochloride (SH) 
and lanthanum carbonate (LC) monotherapy under real-world clinical conditions 
in the USA. METHODS: A post hoc analysis of an open-label, post-marketing study 
of patients (n = 2763) with end-stage renal disease (ESRD) in a real-world clinical 
setting in the USA. The analysis evaluated patients who converted from SH 
monotherapy at baseline to LC monotherapy for 16 weeks (12 week titration 
phase, 4 week maintenance period). Serum phosphate (P) levels and daily P 
binder dose were assessed at baseline and at weeks 12 and 16. RESULTS: A total 
of 953 patients were taking SH monotherapy at baseline; their mean SH dose  
was 7644±3660 mg/day and mean serum P level was 5.88±1.69 mg/dL. After  
16 weeks of LC monotherapy, mean LC dose was 2800±938 mg/day (SH:LC dose-
relativity 2.8) and mean P level was 5.93±1.85 mg/dL. In the subgroup of patients 
(n=191; 20%) receiving SH >7200 to ≤9600 mg/day (mean dose 9294±601 mg/day) 
at baseline, mean P level was 6.10±1.68 mg/dL. After LC treatment, their mean  
LC dose was 3018±800 mg/day (dose-relativity 3.1), and mean P level was 
6.42±1.88 mg/dL. Patients (n=192; 20%) receiving SH >9600 mg/day (mean dose 
13171±2388 mg/day) at baseline had a mean P level of 6.22±1.78 mg/dL. After LC 
treatment, their mean LC dose was 3156±808 mg/day (dose-relativity 4.2) and 
mean P level was 6.25±1.87 mg/dL. CONCLUSIONS: SH:LC dose relativity in the 
overall patient population was 2.8, in agreement with previous studies. However, 
the present study demonstrates that patients who require higher SH doses to 
maintain P control (>7200 mg/day; ~40% of patients) had higher SH:LC dose 
relativities (3.1–4.2). These findings have implications for the cost-effectiveness 




PRODUCTIVITY LOSS COSTS ATTRIBUTABLE TO OVERWEIGHT OR OBESITY  
IN WORKING ASTHMA PATIENTS IN THE UNITED STATES  
Choi IS1, Chang CW1, Kim CM2, Suh DC1 
1Chung-Ang University, Seoul, South Korea, 2Catholic University College of Medicine, Seoul, 
South Korea  
OBJECTIVES: To estimate annual productivity loss costs attributable to being 
overweight or obese in working adults with asthma patients in the US. 
METHODS: Working asthma patients (18-64 years old) were identified using the 
2003-2009 Medical Expenditure Panel Survey (MEPS). Asthma patients were 
identified by self-reported diagnosis, Clinical Classification Codes of 128, or ICD-
9-CM code of 493 and the identified patients were classified as normal-weight 
(18.5≤BMI<25), overweight (25≤BMI<30), and obese (BMI≥30). Productivity loss 
costs, which were measured based on missed work days due to illness or injury 
for one year and the hourly wage, were estimated using a two-part model to 
adjust for patients with zero costs. To estimate the productivity loss costs 
attributable to being overweight or obese, costs were estimated by assuming 
every patient is overweight or obese (i.e., treating the indicator variable as equal 
to 1) and re-estimating by assuming every patient is normal (i.e., treating the 
indicator variable as equal to 0). Then, the mean differences between the two 
estimated costs were considered the productivity loss costs attributable to 
overweight or obesity in asthma patients. All costs were converted to 2011  
US dollars using the Consumer Price Index. RESULTS: Annual average 
productivity loss costs attributable to obesity were $697(95%CI:$614-$780) per 
patient, 45% higher than overweight (at $480, 95%CI:$397-$563) and 92% higher 
than normal (at $363, 95%CI:$298-$428). The productivity loss costs in working 
asthma patients increased as patients were obese, older, or female. Also, the 
productivity loss costs attributable to overweight or obesity in working asthma 
patients were estimated at $89 (95%CI:$87-$91) or $250 (95%CI:$246-$254) per 
person per year, respectively. CONCLUSIONS: The productivity lost costs 
attributable to overweight and obesity in working US adults with asthma were 
substantial. To reduce the economic burden of treating asthma patients and 
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OBJECTIVES: Polycystic kidney disease (PKD) is a genetic disorder affecting 
nearly 1 in 1000 Americans. Autosomal dominant PKD (ADPKD) occurs in both 
children and adults with symptoms often occurring in middle age. The objective 
of this retrospective study was to assess hospital-based utilization among 
patients with ADPKD. METHODS: A retrospective study of 1409 patients 
hospitalized in 2009 with a diagnosis of ADPKD in 71 hospitals continuously 
submitting over 36 months from the MedAssets health system database was 
conducted. Subsequent hospital visits were identified over a 24 month follow-up 
period. Age and gender as well as clinical complications, comorbidities and 
measures of utilization including number of visits and length of stay (LOS) were 
described. Multivariate regression was used to identify significant drivers of 
hospital-based utilization. RESULTS: The sample population had a mean age of 
50.6 years and was 51% male. Patients had an average of 17 outpatient and 2.5 
inpatient visits. Average LOS was 20.6 days, 45% were diagnosed with end stage 
renal disease (ESRD) and 24% received hemodialysis. Over 15.0% required a 
kidney transplant while 3.3% died in the hospital. Comorbidities included 
diabetes 21.9%, congestive heart failure (CHF) 12.6%, cardiopulmonary disease 
(CPD) 14.7%, cardiovascular disease (CVD) 11.3% and malignancy/tumor 12.3%. 
ESRD (1.3 visits, P<0.001), kidney transplant (2.0 visits, p<.0001), (1.4 visits, 
p<.0001), CPD (1.3 visits, p<.0001), CVD (1.4 visits, p<.0001), malignancy (1.3 visits, 
p<0.05) and previous myocardial infarction (1.3 visits, p<0.05) were associated 
with more visits. Similarly, ESRD (1.8 days, <.0001) and kidney transplant (1.5 
days, p=0.0005) were significantly associated with higher inpatient LOS. 
CONCLUSIONS: Patients with ADPKD consume a significant amount of health 
care resources, especially patients reaching the end stage of the disease. Further 
research is required to understand the effect of interventions/treatments on 
mitigating the progress of this disease.  
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OBJECTIVES: To assess patient emergency department (ED) waiting time, 
hospitalization rate immediately following ED visit, number of medications 
prescribed, and length of stay in ED among practices with various levels  
of electronic health record (EHR) functionality pertaining to mental illness-
related ED visits. METHODS: Data from 2006-2009 Centers for Disease Control 
and Prevention National Hospital Ambulatory Medical Care Survey ED files were 
used for this retrospective, cross-sectional study. Mental disorders were 
identified via: 1) International Classification of Diseases, Ninth Revision, Clinical 
Modification codes based on definitions by American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, and 2) mental 
health-related reason for visits as determined by the National Center for Health 
Statistics. EHR use among organizations was classified as no EHR, some EHR, 
basic EHR, and fully functional EHR based on the number and level of available 
features. Negative binomial regression models were applied using waiting time 
and visit length as outcome variables, while logistic and ordered logistic 
regression models were applied using hospitalization rate and number of 
medications prescribed as dependent variables, respectively. Regression 
analyses adjusted for patient demographics (age, gender, race/ethnicity, 
region/location, education, income, insurance status), level of triage and 
comorbidity, and hospital ownership status. To provide national estimates, all 
results were weighted and used standard errors calculated via Taylor-series 
approaches. RESULTS: Of the 24.3 million ED visits identified, 37.2%, 33.4%, and 
6.0% included some, basic, and fully functional EHRs, respectively. Having any 
sort of EHR was associated with 24% greater odds of hospitalization (p=0.032). 
